
Press Release


Cipla announces Q2 FY 1213 Unaudited Financial Results


Mumbai, India, 5th November 2012: Cipla Limited (BSE: 500087, NSE : CIPLA) today announced its Unaudited Financial Results for the quarter ended September 30, 2012 (Q2).


Key Financial & Performance Highlights Q2 FY1213 vis-a-vis Q2 FY1112:

- Gross revenues grew by 23.6% to Rs. 2220 cr, up from Rs. 1796 cr in Q2 FY1112
- Operating margins grew by 57.7% to Rs. 677 cr, up from Rs. 429 cr in Q2 FY1112
- Profit after tax grew by 61.8% to Rs. 500 cr during Q2 FY1213, up from Rs. 309 cr (Q2 FY1112)









Profit & Loss Highlights:

- Material cost at 36.3% of Total Sales decreased by 4.2% during Q2 FY1213 as compared to Q2 FY1112.
- Operating margins increased by 57.7% and is at 30.5% of Income from Operations during Q2 FY1213 as compared to 23.9% during Q2 FY1112.
- Profit after tax increased by 61.8% to Rs. 500 cr during Q2 FY1213 as compared to Rs. 309 cr during Q2 FY1112.

Performance Review:

Domestic business:

- Domestic revenues grew by 13.5% to Rs.962 cr during Q2 FY1213, up from Rs. 847 cr during Q2 FY1112.
- The growth in domestic revenues was largely on account of growth in anti-asthma, anti-biotics and cardiovascular therapy segments.

International business:

- Exports of formulations grew by 38.2% to Rs. 1039 cr during Q2 FY1213, up from Rs. 752 cr during Q2 FY1112.
- Exports of APIs grew by 9.0% to Rs. 174 cr during Q2 FY1213, from Rs. 159 cr during Q2 FY1112.
- The growth in export revenues was primarily due to growth in anti-depressants, anti-ulcerant and anti-asthma segments.

About Cipla:

Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.

With a turnover of over US $ 1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. (www.cipla.com).

Media Contact:

Finance	**Corporate Communications**	
Ajay Luharuka	Antara Mukherjee	Jaisingh Balakrishnan
Contact No.: 022 – 23025435	Contact No.: 022 – 23025810	Contact No.: 022 - 23025813
E-Mail: ajay@cipla.com	E-Mail: antara.mukherjee@cipla.com	E Mail: jaisingh.krishnan@cipla.com